What Ascentage Pharma Group International's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 4 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 4 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Yang Dajun | Chairman and CEO | May 21 | Exercise / conversion · M | +92,746 | — | — | 405,280 |
| Yang Dajun | Chairman and CEO | May 21 | Exercise / conversion · M | +95,575 | — | — | 1,193,569 |
| Zhai Yifan | Chief Medical Officer | May 21 | Exercise / conversion · M | +95,575 | — | — | 1,193,569 |
| Zhai Yifan | Chief Medical Officer | May 21 | Exercise / conversion · M | +92,746 | — | — | 405,280 |
Loading...
